Helvetica Chimica Acta – Vol. 95 (2012)
2033
1 H); 4.47 – 4.36 (m, 3 H); 4.31 (dd, J ¼ 8.5, 6.1, 1 H); 3.22 (dt, J ¼ 11.8, 11.7, 5.0, 1 H); 3.15 – 3.02 (m,
1 H); 2.96 (dd, J ¼ 14.3, 6.4, 1 H); 2.80 (dd, J ¼ 12.0, 8.9, 1 H); 2.33 (dd, J ¼ 14.3, 11.6, 1 H); 2.32 – 2.08
(m, 2 H); 1.54 (s, 3 H); 1.42 (s, 3 H); 1.36 (s, 3 H); 1.29 (s, 3 H). 13C-NMR (75 MHz, CDCl3): 177.4; 171.8;
142.8; 128.6; 128.2; 127.4; 126.9; 126.8; 1110.5; 110.2; 76.7; 74.9; 74.7; 728; 51.0; 42.5; 41.4; 39.4; 32.2; 27.5;
27.4; 25.3; 25.2. HR-EI-MS: 469.1867 ([M ꢀ 15]þ, C27H32O8þ ; calc. 469.1862). Anal. calc. for C27H32O8: C
66.9, H 6.7; found: C 67.1, H 6.9.
2.4. (1R,2R,3S,4S,5S,6R)-5-(4-Bromocinnamoyloxy)-6-hydroxy-1,2;3,4-di(isopropylidenedioxy)cy-
clohexane (¼(3aS,4S,5R,5aR,8aR,8bS)-Hexahydro-5-hydroxy-2,2,7,7-tetramethylbenzo[1,2-d:3,4-d’]
bis[1,3]dioxol-4-yl (2E)-3-(4-Bromophenyl)prop-2-enoate; 2b). Epoxide 1 (600 mg, 2.47 mmol) [6],
potassium para-bromocinnamate (2.40 g, 8.60 mmol), freshly recrystallized 18-crown-6 (2.40 g,
9.00 mmol) [8], para-bromocinnamic acid (576 mg, 2.47 mmol), Bu4NI (200 mg, 0.54 mmol), DMF
(6 ml), 1,2-dimethoxyethane (6 ml), and HMPA (2 ml) were mixed in a pressure tube, sealed under Ar,
and heated to 1278 for 115 h under vigorous stirring. Reaction progress was monitored by TLC (hexanes/
AcOEt 2 :1, CAM/UV). After final cooling, the mixture was diluted with H2O and Et2O, and the phases
were separated. The aq. phase was twice extracted with additional Et2O, and the combined org. phases
were washed twice with sat. Na2CO3 and with brine. Following drying and concentration in the usual
fashion, the residue was purified by FC (hexanes/AcOEt 4 :1, 0.1% Et3N on Et3N-neutralized silica) to
provide 103 mg of the undesired diastereoisomer in the first fraction and 487 mg of the desired isomer,
2b, in the second fraction, in addition to 421 mg of material in a mixed fraction. The mixed fraction was
repurified in the same manner to obtain an additional 303 mg of 2b, for a total of 790 mg in 68% yield.
Colorless amorphous gel. Rf (hexanes/AcOEt 2 :1) 0.29. [a]2D0 ¼ 161.5 (c ¼ 1.0, CHCl3). IR (CHCl3): 3554,
3022, 2995, 2937, 171, 1638, 1488, 1385, 1312, 1167, 1072, 1041, 1010, 900, 860, 803, 734. 1H-NMR
(300 MHz, CDCl3): 7.61 (d, J ¼ 16.0, 1 H); 7.45 (pseudo-d, J ¼ 8.4, 2 H); 7.30 (pseudo-d, J ¼ 8.5, 2 H);
6.43 (d, J ¼ 16.0, 1 H); 5.06 (dd, J ¼ 11.4, 8.3, 1 H); 4.45 (dd, J ¼ 6.2, 3.2, 1 H); 4.42 (dd, J ¼ 6.2, 3.2, 1 H);
4.30 (dd, J ¼ 8.1, 5.9, 1 H); 4.23 (dd, J ¼ 7.9, 6.1, 1 H); 3.64 (dd, J ¼ 11.2, 8.2, 1 H); 2.90 (br. s, 1 H); 1.49
(s, 3 H); 1.48 (s, 3 H); 1.34 (s, 3 H); 1.31 (s, 3 H). 13C-NMR (75 MHz, CDCl3): 166.4; 144.3; 133.0; 132.0;
129.4; 124.6; 118.0; 109.5; 109.4; 78.9; 76.2; 75.5; 75.2; 73.5; 71.4; 27.7; 27.4; 25.4; 25.3. HR-EI-MS:
468.0794 (Mþ, C21H25BrO7þ ; 468.0784). Anal. calc. for C21H25BrO7: C 53.74, H 5.37; found: C 53.73, H
5.47.
2.5. 5-(4-Bromocinnamoyloxy)-6-(hexa-3,5-dienyloxy)-2,2,7,7-tetramethylhexahydrobenzo[1,2-d;
3,4-d’]bis[1,3]dioxol-4-ol (¼(3aS,4R,5R,5aS,8aS,8bS)-5-{[(2E)-3-(4-Bromophenyl)prop-2-enoyl]oxy}-
hexahydro-2,2,7,7-tetramethylbenzo[1,2-d:3,4-d’]bis[1,3]dioxol-4-yl (3E)-Hexa-3,5-dienoate; 3b). Com-
pound 2b (460 g, 1.0 mmol) was dissolved in freshly distilled CH2Cl2 (10 ml) along with hexa-3,5-dienoic
acid (224 mg, 2.0 mmol) and cat. DMAP (10 mg), and the yellow soln. was cooled to 08 under stirring.
DCC (391 mg, 1.9 mmol) was added, and the mixture was stirred for 4 h. The mixture immediately
turned slightly orange and formed insoluble material. TLC showed completion of the reaction, and the
mixture was diluted with Et2O and filtered through a Celite plug. Solvent was removed under reduced
pressure, and FC (hexanes/AcOEt 8 :1, 0.1% Et3N on Et3N-neutralized silica) of the crude mixture
provided 450 mg (80%) of 3b. Colorless gel. Rf (hexanes/AcOEt 4 :1) 0.59. [a]2D0 ¼ 35.3 (c ¼ 0.50,
CHCl3). IR (CHCl3, c ¼ 5 mg/ml): 3027, 2992, 2935, 1740, 1721, 1637, 1488, 1385, 1309, 1209, 1165, 1073,
1
1008, 909, 855, 820, 782, 743, 679. H-NMR (300 MHz, CDCl3): 7.53 (d, J ¼ 16.0, 1 H); 7.45 (pseudo-d,
J ¼ 8.3, 2 H); 7.29 (pseudo-d, J ¼ 8.4, 2 H); 6.31 (d, J ¼ 16.0, 1 H); 6.07 (ddd, J ¼ 16.6, 10.1, 10.1, 1 H);
5.93 (dd, J ¼ 14.8, 10.7, 1 H); 5.56 (ddd, J ¼ 14.7, 7.2, 7.2, 1 H); 5.20 – 5.05 (m, 2 H); 4.90 (d, J ¼ 16.4,
1 H); 4.84 (d, J ¼ 9.8, 1 H); 4.55 – 4.49 (m, 2 H); 4.38 – 4.28 (m, 2 H); 3.02 (d, J ¼ 7.2, 2 H); 1.50 (s, 3 H);
1.48 (s, 3 H); 1.32 (s, 3 H); 1.31 (s, 3 H). 13C-NMR (75 MHz, CDCl3): 1703; 165.3; 144.3; 136.0; 134.4;
132.9; 131.9 (2 ꢁ CH); 129.4 (2 ꢁ CH); 124.7; 124.6; 117.6; 116.8; 109.51; 109.46; 76.1; 75.9; 74.7 (2 ꢁ
CHC2OR); 71.2; 71.0; 37.8; 27.42; 27.39; 25.6; 25.6. HR-EI-MS: 562.1198 (Mþ, C27H31BrO8þ ; calc.
562.1202). Anal. calc. for C27H31BrO8: C 57.56, H 5.55; found: C 57.41, H 5.65.
2.6. (1S,2S,3S,4S,4aR,6aS,7S,10aR,13aR)-7-(4-Bromophenyl)-1,2;3,4-di(isopropylidenedioxy)-
2,3,4,4a,6a,7,10a,11-octahydro-1H-dibenzo[b,f][1,4]dioxonine-6,12(10H,13aH)-dione (¼(3aS,3bS,6aS,
6bR,8aS,9S,12aR,15aR,15bS)-9-(Bromophenyl)-3a,3b,6a,6b,9,10,12a,13,15a,15b-decahydro-2,2,5,5-tetra-
methyl-8H-benzo[f]bis[1,3]dioxolo[3,4 :5,6]benzo[1,2-b][1,4]dioxonine-8,14(8aH)-dione; 4b). Com-
pound 3b (400 mg, 0.71 mmol) was dissolved in 90 ml of 1,2,4-trichlorobenzene, and the soln. was